Brief: Sumitomo Pharma America Announces Enzomenib (Dsp-5336) Receives FDA Orphan Drug Designation For Treatment Of Acute Lymphoblastic Leukemia
30/07/2026 13:08
BRIEF-Sumitomo Pharma America Announces Enzomenib (Dsp-5336) Receives FDA Orphan Drug Designation For Treatment Of Acute Lymphoblastic Leukemia July 30 (Reuters) - Sumitomo Pharma Co Ltd 4506.T:
SUMITOMO PHARMA AMERICA ANNOUNCES ENZOMENIB (DSP-5336) RECEIVES FDA ORPHAN DRUG DESIGNATION FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
Source text: ID:nBw3QzS1pa
Further company coverage: 4506.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sumitomo Pharma
See all newsSumitomo Pharma America Announces First Patient Receives Treatment In Phase 1/2A Study For Investigational Therapy Dsp-3077 For Retinitis Pigmentosa
Regarding A Report Concerning Sumitomo Pharma ( Company's Views On Gcr August 7 Report)
Brief: Sumitomo Pharma - Gotham City Research's August 3 Report Contains Numerous Statements That Are Clearly Inconsistent With Facts
Brief: Gotham City Research Holds Short Positions In Sumitomo Chemical And Sumitomo Pharmaceutical
Table: Sumitomo Pharma -Q1 group results (IFRS)